Baseline characteristics of the total chronic obstructive pulmonary disease (COPD) cohort

Total patients127
Continuous variables
 Age years66.8±8.61
 Smoking history pack-years50.3±28.2
 Body mass index kg·m–227.0 (6.69)
 Fat-free body mass %48.9 (21.5) (n=125)
 White blood cells count ×109 L–17.60 (2.20) (n=126)
 Eosinophils count ×109 L–10.20 (0.20) (n=126)
 Eosinophils %2.94 (3.08) (n=126)
 Neutrophils count ×109 L–14.80 (1.70) (n=126)
 Fibrinogen g·L–14.80 (1.02) (n=114)
 C-reactive protein mg·L–15.00 (8.00)
 Eosinophils %#1.93 (5.05) (n=83)
 Neutrophils %#47.0 (70.4) (n=83)
 FEV1 % pred46.7 (25.3) (n=126)
 ΔFEV1 % of baseline4.93 (21.1) (n=85)
 FEV1 reversibility % of pre-bronchodilator FEV1+11.2 (17.0) (n=105)
KCO %69.2 (30.7) (n=122)
TLCO %57.9 (29.5) (n=122)
 CAT score16.0 (10.0) (n=126)
 6MWT distance m300 (170) (n=125)
 EXACT-PRO score37.0 (12.0) (n=101)
 Exacerbation rate in year before study2.00 (2.00)
 Exacerbation rate in first year of study2.94 (3.91)
 Eosinophilic exacerbation rate in first year of study0.99 (2.02)
 Follow-up in first year of study years1.00 (0.02)
Categorical variables
  Male68 (54)
  Female59 (46)
 Current smoker§
  Yes54 (43)
  No73 (57)
 Frequent exacerbators in year 0
  Yes99 (78)
  No28 (22)
 Use of ICS at enrolmentƒ
  Yes113 (89)
  No14 (11)
 Sputum eosinophils >3%#
  Yes27 (33)
  No56 (67)
 Blood eosinophils ≥2%
  Yes86 (68)
  No40 (32)
 Bacteria present##
  Yes57 (52)
  No53 (48)
 Virus present¶¶
  Yes18 (17)
  No85 (83)
 Blood eosinophils ≥200 cells·μL–1
  Yes90 (71.4)
  No36 (28.6)

Data are presented as n for patient numbers, mean±sd or median (interquartile range) for continuous variables, or n (%) for categorical variables. FEV1: forced expiratory volume in 1 s; KCO: transfer coefficient of the lung for carbon monoxide; TLCO: transfer factor of the lung for carbon monoxide; CAT: COPD Assessment Test; 6MWT: 6-min walk test; ICS: inhaled corticosteroid. #: sputum eosinophil and neutrophil percentage at baseline is reported (“baseline” is equal to enrolment if good quality data (squamous cell contamination <30%) is present at enrolment or the next (pre-exacerbation) stable visit with quality data within 4 months of enrolment); : calculated as FEV1 at month 12×100/FEV1 at enrolment; +: calculated as (post-bronchodilator FEV1–pre-bronchodilator FEV1)/pre-bronchodilator FEV1×100; §: smoking status report derived from American Thoracic Society Division of Lung Disease questionnaire ATS-DLD-78A; ƒ: ICS use was coded as “Yes” if one of the following medications/inhalers was on the list: Symbicort, Seretide, QVAR, Fostair, beclomethasone, beclomethasone/formoterol, beclomethasone dipropionate, Clenil, fluticasone/salmeterol or budesonide/formoterol; ##: sputum sampling, measured by culture (includes Haemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae, Staphylococcus aureus and Pseudomonas aeruginosa); ¶¶: sputum sampling, measured by PCR (includes adenovirus, enterovirus, influenza, coronavirus, metapneumovirus, bocavirus, parainfluenza, respiratory syncytial virus and rhinovirus).